Pulmatrix Inc Dossier
Qualitative Analysis
Business overview
Pulmatrix, Inc. (NASDAQ: PULM) is a clinical-stage biopharmaceutical company historically focused on developing novel inhaled therapeutic products using its patented dry powder delivery technology, iSPERSE. The company's proprietary pipeline has included PUR3100 for acute migraine, PUR1800 for acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for allergic bronchopulmonary aspergillosis (ABPA). However, Pulmatrix has transitioned into a virtual operating model with minimal direct operations, having paused clinical development to focus on licensing or monetizing its clinical assets.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Definitive merger agreement under which Pulmatrix will acquire Eos SENOLYTIX in an all-stock transaction.
Expected impact: Combined entity will operate under the Eos SENOLYTIX name and trade on Nasdaq under the ticker EOSX, focusing on age-related muscle loss and sarcopenia.
Actively seeking to out-license or monetize legacy clinical assets and the proprietary iSPERSE dry powder inhalation technology platform.
Expected impact: Generates non-dilutive capital and retains potential upside, such as the 2% royalty on ex-US sales of PUR1900 and 50/50 shared US rights with Cipla.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To transition the company's focus toward Eos's pipeline targeting age-related muscle loss and sarcopenia, leveraging a concurrent $19 million private financing.
Financial impact: Pre-merger Pulmatrix stockholders will retain an estimated 6% ownership of the combined company, while Eos stockholders and financing investors will hold approximately 94%.
Strategic Partnerships
Cipla is responsible for the clinical development of PUR1900 (an inhaled antifungal) in India, including an upcoming Phase 3 trial.
Terms: Pulmatrix is entitled to receive a 2% royalty on potential future net sales of PUR1900 by Cipla outside the US, and shares US rights 50/50 with Cipla.